Drug Profile


Alternative Names: Atomoxetine hydrochloride; LY 139603; Strattera; Tomoxetine; Tomoxetine hydrochloride

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Propylamines
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • Discontinued Alzheimer's disease; Major depressive disorder

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 Aug 2015 No recent reports on development identified - Phase-III for Attention-deficit hyperactivity disorder (In adults) in China (PO)
  • 30 Jun 2013 Registered for Attention-deficit hyperactivity disorder (in adults) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top